Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration

Clinical Chemistry

Volumn 57, Issue 12, 2011, Pages 1748-1756

  Schwaninger, Andrea E ^a   Meyer, Markus R ^a   Barnes, Allan J ^b   Kolbrich Spargo, Erin A ^b,c   Gorelick, David A ^b   Goodwin, Robert S ^b   Huestis, Marilyn A ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c Southwest Institute of Forensic Science Dallas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYL ALPHA METHYLDOPAMINE; 3,4 DIHYDROXYAMPHETAMINE; 3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; DRUG METABOLITE; GLUCURONIDE; SULFATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; TOXICOKINETICS; TRANSPORT KINETICS; URINALYSIS;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; GLUCURONIDES; HUMANS; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SULFURIC ACID ESTERS;

EID: 82755195766     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.172254     Document Type: Article

References (32)

1. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ. Stereospecific analysis and enantiomeric disposition of 3,4- methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 1999;45:1058-69. (Pubitemid 29340544)
2. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs [Review]. Can Med Assoc J 2001;165:917-28. (Pubitemid 34028233)
3. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration Office of Applied Studies. Results from the 2009, National Survey on Drug Use and Health, vol. I. Summary of National Findings (http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf) (Accessed October 2011).
4. Monks TJ, Jones DC, Bai F, Lau SS. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity [Review]. Ther Drug Monit 2004;26:132-6. (Pubitemid 38501206)
5. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition [Review]. Ther Drug Monit 2004;26:137-44. (Pubitemid 38501207)
6. Easton N, Marsden CA. Ecstasy: are animal data consistent between species and can they translate to humans [Review]? J Psychopharmacol 2006;20:194-210.
7. Mueller M, Kolbrich EA, Peters FT, Maurer HH, McCann UD, Huestis MA, Ricaurte GA. Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans. Ther Drug Monit 2009;31:367-73.
8. Baumann MH, Zolkowska D, Kim I, Scheidweiler KB, Rothman RB, Huestis MA. Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 2009;37:2163-70.
9. McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, et al. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 2008;200:439-50.
10. Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, Colado MI. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl) 2001;154:251-60. (Pubitemid 32247186)
11. Gollamudi R, Ali SF, Lipe G, Newport G, Webb P, Lopez M, et al. Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 1989;10:455-66. (Pubitemid 20084630)
12. Bai F, Lau SS, Monks TJ. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol 1999;12:1150-7. (Pubitemid 30013524)
13. Hiramatsu M, Kumagai Y, Unger SE, Cho AK. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 1990;254:521-7. (Pubitemid 20262091)
14. Miller RT, Lau SS, Monks TJ. 2,5-Bis-(glutathion-S-yl)-alpha- methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 1997;323:173-80. (Pubitemid 27152268)
15. Mueller M, Yuan J, Felim A, Neudörffer A, Peters FT, Maurer HH, et al. Further studies on the role of metabolites in (+/-)-3,4- methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab Dispos 2009;37:2079-86.
16. Schwaninger AE, Meyer MR, Huestis MA, Maurer HH. Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in human urine. J Mass Spectrom 2011;46:603-14.
17. Maurer HH. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther Drug Monit 1996;18:465-70. (Pubitemid 26264669)
18. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("Ecstasy"). Toxicol Lett 2000;112:133-42. (Pubitemid 30138114)
19. Shima N, Katagi M, Kamata H, Zaitsu K, Kamata T, Nishikawa M, et al. Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3- methoxymethamphetamine (HMMA), in humans and rats. Xenobiotica 2008;38:314-24. (Pubitemid 351264448)
20. Schwaninger AE, Meyer MR, Zapp J, Maurer HH. Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4- dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. Toxicol Lett 2011;202:120-8.
21. Schwaninger AE, Meyer MR, Zapp J, Maurer HH. The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R-and S-3-methoxymethamphetamine 4-O-glucuronides. Drug Metab Dispos 2009;37:2212-20.
22. Pizarro N, Ortuno J, Farre M, Hernandez-Lopez C, Pujadas M, Llebaria A, et al. Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 2002;26:157-65. (Pubitemid 34309726)
23. Abraham TT, Barnes AJ, Lowe RH, Kolbrich Spargo EA, Milman G, Pirnay SO, et al. Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. J Anal Toxicol 2009;33:439-46.
24. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS [see Comments]. J Anal Toxicol 1996;20:432-40. (Pubitemid 26327466)
25. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, et al. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 2001;14:1203-8. (Pubitemid 32911458)
26. Peters FT, Kraemer T, Maurer HH. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clin Chem 2002;48:1472-85.
27. Mueller M, Kolbrich EA, Peters FT, Huestis MA, Ricaurte GA, Maurer HH. Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma. Anal Bioanal Chem 2009;393:1607-17.
28. Pirnay SO, Abraham TT, Huestis MA. Sensitive gas chromatography-mass spectrometry method for simultaneous measurement of MDEA, MDMA, and metabolites HMA, MDA, and HMMA in human urine. Clin Chem 2006;52:1728-34. (Pubitemid 44330707)
29. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 2008;30:320-32.
30. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 2000;49:104-9. (Pubitemid 30068287)
31. Meyer MR, Maurer HH. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferasecatalyzed dopamine 3-methylation. Chem Res Toxicol 2009;22:1205-11.
32. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003;3:136-58. (Pubitemid 36850156)